The marijuana industry is still driven by men – but these 5 woman are changing 4/20 and upending the industry by focusing on the future.
Since it started becoming legal, the marijuana industry has been filled with bros trying to run everything. Some smart, some shysters – they have had an oversized say in the direction of where legal marijuana is going. But woman are having a moment, and a huge impact in the millions of newly legal consumers. Be it in imagine, politics, or products, woman are making game changing changes on how cannabis is mainstreaming. When 4/20 started in, the landscape was way different, the 5 woman are changing 4/20 today to a bigger, more mainstream celebration.
Nancy co-founded Wana Brands in 2010, elevating it from her kitchen to an international cannabis edible powerhouse. With North America’s largest distribution footprint, it is a top international brand available in 17 U.S. states, the U.S. territory of Puerto Rico and nine Canadian provinces and territories, generating close to $300 million in retail sales annually across more than 3,000 dispensaries.
As a pioneer in the legal cannabis market, she has shown again and again commitment to research and crafting safe, innovative products. She understands the millions of canna-newbies who is looking for something to pair perfectly with the their non-stoner lifestyle. Under her leadership, Wana was acquired by Canopy Grow, which is owned in part by alcohol behemoth Constellation.
Nancy’s inclusive vision led to an executive team that is 70% female, a rarity in the industry and reflective of her dedication to diversity. Her unique insights have given Wana an advantage as she understand the average consumer, which makes up the bulk of the market.
Senator Patty Murray
Photo by Anna Moneymaker/Getty Images
In the old boys club of Congress, Senator Patty Murray (D-WA) has risen in the ranks thanks to a willingness to focus on a solving problems, thinking of the average citizen and wielding her knowledge and strength. As the third most powerful person in the Senate, she is working with Senate Leader Schumer (D-NY) and a bipartisian group to make significant inroads into federal marijuana policy. Long a champion of veterans, this will benefits those who have served who suffer from PSTD.
Shawna Seldon McGregor
In a sometimes rough and tumble industry with some wacky players, it is good to have a public relations firm you can trust. Mirroring the mainstream industry, Maverick PR, has helped the industry move past the old stoner, bro imagine and move into today. Founded by Shawna Weldon McGregor, she has become the consul to industry executives and a media whisper to keep the good players growing. Shawna’s ability to make marijuana messaging mainstream has been a hallmark of her career. Since the inception of adult use in Colorado, she has led effective publicity campaigns for top brands including Wana, Native Roots, Deep Roots Harvest and Botani. Trusted by leaders, she has been able to understand and guide companies into changes like California sober. Her understand of consumers and media has been invaluable to leaders.
Debra Borchardt
Debra Brochardt was a respected media voice on Wall Street when she jumped in the marijuana world founding Green Market Report. Premiering at time when the industry was still shady and, as one executive said, people would come to meetings and put a gun down, she brought reason and truth to the table. Known for her straight reporting, she has taken on corruption, crazy leaders, and complicated financial deals. Venerable media company, Crains, recognizing the growth of market, acquired the asset and has only helped Brochardt reach her vision. Highlighting legit good companies, Green Market Report has become a must read for investors, politicians, and executives.
With a talent for organization and building infrastructures, Hart jumped into the industry in 2015. Seeing an opportunity to be build infrastructures and platforms she brought her management skills to a variety of companies. As COO of Keneh Ventures She has helped review, fund and partial advisement for some of the investments including GoFire and AI startup WeDream World. Understanding the mainstream appeal, she has been a champion of Cannabition, a state of the art cannabis immersive experience opening next to Planet 13 in Las Vegas. She now has added Managing partner and operations manager of the exhibition alongside her other duties. She shared over the last 8 years the priorities of entrepreneurs and investors have matured as the market for cannabis has grown and become accepted by the general population.
Tariffs are the word of the day – but marijuana consumers need to be ready to see a change also.
From apples to automobiles, hundreds of industries are trying to figure out the new tariffs. What is clear is prices are going up on a random amount of things. But, why is a surprise, is cannabis consumers are being hit by the tariffs also. Although cannabis itself cannot be imported or exported due to federal restrictions, the industry heavily relies on international suppliers for key components like vaporizer hardware, packaging, and cultivation equipment.
For instance, products sourced from China now face cumulative tariffs as high as 45%, including a 10% increase imposed in February 2025. Similarly, imports from Canada and Mexico face 25% tariffs. These measures have particularly affected items like vape cartridges, batteries, and specialized packaging materials, which are difficult to source domestically at competitive prices. As a result, many cannabis companies are passing these increased costs down the supply chain to consumer
The financial burden of these tariffs is substantial. Analysts estimate that most cannabis businesses lack the margin flexibility to absorb a 10%-15% cost increase. This has led to higher retail prices for products like pre-rolls and vaporizers, potentially pushing consumers toward cheaper, unregulated black-market alternatives. Such a shift raises concerns about product safety and could undermine the legal market’s growth.
Additionally, the tariffs have caused stock prices of major cannabis companies like Tilray Brands and Canopy Growth to decline by 5%-10%, reflecting investor concerns over profitability.Smaller businesses, already constrained by high taxes and limited banking access, are particularly vulnerable to these economic pressures.
Efforts to mitigate tariff-related expenses include exploring alternative manufacturing locations in countries like Malaysia or India. However, transitioning production is complex and time-consuming due to logistical hurdles and regulatory compliance requirements. Domestic production is another option but often comes with higher costs and limited capacity.
Packaging regulations in many states exacerbate the situation by requiring child-resistant designs, further limiting affordable domestic alternatives. Some companies are exploring sustainable packaging solutions as a long-term strategy to reduce dependence on volatile international markets.
The ongoing trade tensions show no signs of easing under Trump’s administration, leaving cannabis businesses with little choice but to adapt quickly. Strategies such as diversifying suppliers, investing in automation, and innovating with local materials may help companies weather the storm. However, without significant policy shifts or financial support mechanisms, the industry faces a challenging road ahead.
There is a buzz about sore throats today. While they are most common in colder months, spring allergies bring the pain also. This is often due to postnasal drip, which is when mucus from the nose and sinuses drains down the back of the throat, causing irritation and a scratchy feeling. Overuse of the voice, like talking loudly or singing for long periods, can tire out and strain the muscles in your throat, causing them to feel sore. The good news is cannabis can help a sore throat.
For those seeking natural alternatives to manage cold symptoms, cannabis is emerging as a promising option for throat irritation. Increasing research at medical center specifically targeting sore throats shows early insights. The data suggests cannabinoids and terpenes could offer symptom relief through their unique properties.
Photo by Esther Kelleter / EyeEm/Getty Images
Cannabis contains compounds like THC and CBD, which studies indicate possess anti-inflammatory properties that may reduce throat swelling and irritation. Terpenes such as eucalyptol—found in some strains—are traditionally associated with decongestant effects, potentially easing respiratory discomfort. These components work synergistically to calm inflamed tissues, though their direct impact on sore throats requires further clinical validation.
Smoking cannabis while ill remains controversial due to potential throat irritation from heat and smoke. Instead, experts recommend gentler options:
Edibles/lozenges: THC or CBD-infused products bypass inhalation, delivering localized relief without aggravating the throat.
Cannabis tea: Warm beverages with cannabis extracts may soothe scratchy throats while providing hydration.
Beyond direct throat relief, cannabis may improve overall wellness during illness. THC’s appetite-stimulating properties can combat reduced hunger, while its relaxing effects might promote restorative sleep. CBD’s muscle-relaxing qualities could help alleviate the body aches often accompanying colds.
While preliminary findings are encouraging, users should consult healthcare providers before combining cannabis with conventional cold medications due to potential interactions. Starting with low-dose CBD products may offer benefits without psychoactive effects. As legalization expands, more targeted research is expected to clarify cannabis’s role in respiratory health.
Innovative cannabis formulations—from throat-calming lozenges to anti-inflammatory teas—are redefining how we approach minor ailments. For those navigating cold season, these plant-based solutions present a compelling fusion of traditional herbal wisdom and modern cannabinoid science
Part of the cannabis industry supported the new president, betting he was going to move and move quickly on cannabis – the White House finally commented.
The cannabis industry has been a boon for consumers, medical patients, veterans and legal states, but for the thousands of mom and pop businesses is has been a roller coaster. With a huge demand, it would seem to be easy money, but the federal, tax, and banking restrictions have made it difficult to grow and expand. Part of the industry were all for the new administration assuming they would support positive change, but many in the new cabinet and the House Speaker Mike Johnson are foes. Now the White House finally comments on marijuana industry…and it doesn’t show a clear path.
The administration’s current stance on marijuana reform is marked by inaction, despite campaign promises and earlier signals of support for cannabis-related reforms. A White House official recently confirmed that “no action is being considered at this time” regarding marijuana policy, leaving advocates and industry stakeholders uncertain about the administration’s priorities.
During his campaign, the resident expressed support for rescheduling marijuana under the Controlled Substances Act (CSA), which would move it from Schedule I to Schedule III, easing restrictions on medical use and enabling cannabis businesses to access banking and tax benefits. However, since taking office, no concrete steps have been taken to advance this initiative. A DEA hearing on rescheduling, initially planned for January 2025, was postponed due to procedural appeals and remains unscheduled.
The president has also voiced support for state autonomy in cannabis policy and endorsed state-level legalization initiatives, such as Florida’s failed 2024 ballot measure for recreational marijuana. While this reflects a more favorable stance compared to his first term, his administration has yet to prioritize federal reforms like the SAFE Banking Act, which would facilitate banking services for cannabis businesses. Efforts to include such measures in a government funding bill late last year were unsuccessful.
The delay in federal action has significant implications for the cannabis industry. Rescheduling marijuana could alleviate financial burdens by eliminating restrictions under IRS Code Section 280E and promoting medical research. However, the stalled process leaves businesses navigating regulatory uncertainties and limited financial access.
While stakeholders continue lobbying for reform, the administration appears focused on other priorities such as immigration and foreign policy. Advocates hope the President will leverage his influence to advance cannabis reform, but for now, the issue remains sidelined. Until then the industry struggles and waits.